Every material Form 8-K Fulcrum Therapeutics, Inc. has filed with the SEC since June 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Fulcrum Therapeutics signed a merger agreement on August 16, 2026, under which Slate Medicines will combine with Fulcrum in an all-stock deal, with the combined company to be renamed Slate Medicines. Fulcrum expects to pay its pre-merger stockholders a cash dividend of $270 million, but those holders are expected to own only about 5.0% of the combined company, subject to adjustment based on Fulcrum's net cash at closing.
Pre-merger Fulcrum stockholders are expected to own about 5.0% of the combined company on a fully diluted basis.
Fulcrum expects to declare a cash dividend of $270 million to its pre-merger stockholders in connection with the closing.
A concurrent private placement of approximately $245.0 million is a closing condition, and the closing is expected in the fourth quarter of 2026.
Termination fees are $10 million payable by Fulcrum and $15 million payable by Slate in certain circumstances.
Fulcrum Therapeutics said its vice president of finance and principal accounting officer, Greg Tourangeau, is leaving the company, with his tenure ending August 7, 2026. The board named Chief Financial Officer Alan Musso as principal accounting officer, effective the same date, so one executive now holds both the finance and accounting roles.
Greg Tourangeau's tenure as VP, Finance and principal accounting officer ends August 7, 2026, as previously disclosed in a June 11, 2026 8-K.
Board appointed Alan Musso, chief financial officer, as principal accounting officer on August 9, 2026, effective August 7, 2026.
Musso will receive no additional compensation for the added role.
Fulcrum Therapeutics approved cash retention payments for its nine remaining full-time employees, including CEO Alex C. Sapir, CLO Curtis Oltmans and CFO Alan Musso, tied to a change in control or qualifying termination. It also agreed that Vice President, Finance and principal accounting officer Greg Tourangeau will depart, with the date to be agreed, and states the departure is not related to any disagreement on financial or accounting matters.
Retention payments: $370,040 for Alex C. Sapir, $195,480 for Curtis Oltmans and $195,200 for Alan Musso, payable in cash upon a change in control or qualifying termination
Change-in-control benefits extended to remaining employees at Vice President level and above if terminated without cause within six months before a change in control
Greg Tourangeau, VP Finance and principal accounting officer, agreed on June 10, 2026 to depart; departure date not yet set
Restructuring follows discontinuation of pociredir development for sickle cell disease, approved by the board on May 31, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Fulcrum Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →